Conferences | HCP Profiles
Evaluate the impact of new strategies for the treatment of fatty liver disease, Learn about the updates in autoimmune liver diseases evaluation and management, Evaluate the role of sarcopenia frailty and its impact on liver transplants
utilize the latest developments in the diagnosis, staging, and treatment of metabolic-associated steatotic liver disease (MASLD), identify new developments in the diagnosis and treatment of cholestatic, autoimmune, and genetic liver diseases, implement new treatments including the use of immunotherapies for hepatocellular carcinoma.
This program has been planned and implemented in accordance with ACCME Standards for Integrity and Independence. The Loma Linda University School of Medicine Continuing Medical Education Office relies on its CME faculty to provide program content that is free of commercial bias.
The Michigan Medicine Rogel Cancer Center (UMRCC) is an NCI-designated comprehensive cancer center with a history of excellence in cancer care, education, and research
The program will not only address updates on scientific research and guidelines-based practice but will also delve into the aspects of clinical care considerations in the bronchiectasis workplace. This course is geared towards physicians, physicians-in-training, Advanced Practice Providers (APPs), and Allied Healthcare professionals with a focus on bronchiectasis and NTM.
Our conference serves as a forum for researchers, scientists, academicians, policymakers, and industry experts from all backgrounds to convene and share their expertise and insights. Attendees will have the opportunity to engage in stimulating discussions, exchange ideas, and establish valuable connections.
The RegenBio Summit is a gathering of thought leaders and experts at the forefront of regenerative medicine, biomanufacturing, and translational research. This dynamic event aims to accelerate the transformation of next-generation biotherapeutics. Our focus extends across diverse medical specialties, including orthopedics, oncology, cardiovascular medicine, neurosciences, and transplantation, among other medical and surgical specialties.
The meeting will begin on the evening of Monday, December 9, 2024, and end after lunch on Thursday, December 12. To maximize interactions amongst participants, this meeting is now IN-PERSON only - no virtual attendance is available. Abstracts should contain new and unpublished material. Selection of material for oral and poster presentations will be made by the organizers and session chairs.
Discuss predictive markers in clinical use with cancer immunotherapies and their relevance to cancer immunotherapy approaches, Summarize recent updates in newly approved FDA immunotherapies and their impact on diagnostics, Describe the importance of pathological response evaluation and its correlation with outcomes, specifically in the neoadjuvant setting.
The annual meeting will offer a chance to meet friends, network and hear all the latest developments and research in pharmacology from industry experts and emerging investigators.
Improve knowledge, competence, and utilization of the most recent evidence-based clinical practice guidelines, Bolster competence in the management of patients with complex comorbidities and less common medical conditions, thereby improving patient outcomes and safety, Improve skills/strategies in the use of newer equipment/technologies and improve performance within multidisciplinary protocols in order to optimize patient outcomes.
Course content includes: American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care; basic life support skill, including effective chest compressions, use of a bag-mask device and use of an (AED); recognition and early management of respiratory and cardiac arrest; recognition and early management of peri-arrest conditions such as symptomatic bradycardia; airway management; related pharmacology; management of acute coronary syndromes (ACS) and stroke
